Taipei Medical University Institutional Repository:Item 987654321/6021
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 45065/58241 (77%)
造访人次 : 2247689      在线人数 : 266
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/6021


    题名: 探討補益類中藥----龜鹿兩仙膠作用於人體體幹細胞增生與分化之效能評估研究
    To investigate the influence of Guilu Erxian Gao on the proliferation and differentiation of human tissue stem cells
    作者: 邱靖晴
    Ching-Ching Chiu
    贡献者: 細胞及分子生物研究所
    关键词: 龜陸兩仙膠
    龜板
    Guilu Erxian Gao( GEG)
    Tortoise plastron (T.P.)
    日期: 2006
    上传时间: 2009-09-11 15:50:51 (UTC+8)
    摘要: 龜鹿兩仙膠( GEG)為傳統醫學上具骨修復效能與治療骨質疏鬆症的中藥複方，但至今其藥理仍缺乏科學驗證。本論文的目的是利用人體造血及間質幹細胞的特性來系統性的探討龜鹿兩仙膠對成體組織細胞增生與分化的影響及功能性基因體的評估，藉此鑑定出龜鹿兩仙膠之藥理作用。實驗結果顯示：(1)造血系統的影響方面：由血球前趨細胞群落形成分析( Colony forming assay；C.F.A.)得知龜鹿兩仙膠( GEG)會增多血球群落總數，並促進顆粒與巨噬細胞系造血細胞之分化( granulocyte and macrophage lineage )；而其動物性成份—龜板( T.P.)與鹿角( C.C.)僅能增多總群落數但對造血性幹細胞的分化無影響。(2)非造血系統的影響方面：(a)神經分化方面，除具有分化為成熟神經細胞的能力也保有其原具有的神經膠細胞分化潛能；(b)對血管分化生成具有促進效果；(c)軟骨分化方面，會加速並增多軟骨球的生成；(d)硬骨分化方面除會加速並增加骨礦化外( Bone mineralization)，也有加速骨母細胞增生與分化的效用。
    除上述之藥效應證外，從成分藥材分析結果發現(1)動物性中藥— 龜板為龜鹿兩仙膠促進硬骨與軟骨分化之主要效力成份﹔(2)人蔘為促進血管分化生成效能之成份。但基於保育觀念興盛，本論文進而探索可能取代龜板之中藥材，我們利用傳統中藥的經驗醫學進行蒐尋，找出七個與骨生成與骨修復相關的中藥材— 丹蔘( S.M.)、骨碎補( D.F.)、何首烏( P.M.)、杜仲( E.U.)、續斷( D.A.)、山茱萸( C.O.)、牛膝( A.B.)…等。先藉由Von-Kossa染色篩選出最可能取代龜板之中藥材為骨碎補、續斷、牛膝。接著進行與龜鹿兩仙膠相同的實驗，以評估取代效用。結果顯示(1)取代方對造血系統之影響方面：骨碎補與欲取代之龜板相似，能增多血球總群落數但對造血性幹細胞的分化無影響。另ㄧ中藥牛膝具有增多紅血球系母細胞並降低顆粒與巨噬細胞系母細胞群落形成。(2)取代方對非造血系統影響方面：杜仲、丹蔘能促進血管之分化生成；骨碎補、續斷會促進軟骨球形成，而骨碎補、續斷、牛膝則會促進硬骨分化。綜合上述實驗結果可知骨碎補與續斷可能為最具取代龜板的中藥材。
    在分子層次更進一步驗證龜鹿兩仙膠之分子藥理，在間質幹細胞分化為硬骨細胞的早期，不論龜鹿兩仙膠、龜板或欲用來取代龜板之骨碎補與牛膝，皆會降低osteoclast相關基因IL-11的表現；在分化為硬骨細胞的中期則不論龜鹿兩仙膠、龜板或欲用來取代龜板之骨碎補與牛膝，osteoblast相關基因BMP-2皆會增強表現，且在分化為硬骨細胞的晚期除牛膝外也都會增強細胞基質Type I Collagen的表現。
    雖說骨碎補之龜板替代方具有促進硬骨與軟骨分化的效用，但由於功能性基因體上的表現仍有些許異同且在鹼性磷酸酶染色與鹼性磷酸酶活性分析實驗中，骨碎補在100μg/mL具有加速骨母細胞分化的能力但在200μg/mL時卻出現類似細胞毒性反應使細胞停止生長與分化，藥物有效且安全的作用濃度狹窄，因此新配方的組成仍待討論，有待更進一步進行動物實驗驗證其效果並尋找適合的安全使用劑量。
    Guilu Erxian Gao( GEG) is a well known traditional Chinese medicine that has been frequently used in the treatment of osteoporosis and other bone diseases, however, the pharmacological base function has not been elucidated.
    In the present study, we utilize human tissue stem cell to evaluate the influences of GEG on the hematopoietic and non-hematopoietic mesenchymal system. In the hematopoietic response, GEG shown to elevate the total hematopoietic colony numbers, and to promote Granulocyte and Macrophage lineage differentiation. In non- hematopoietic stem/progenitor system, GEG shown to promote osteogenesis, chondrosphere and endothelial tube formations, and sustain the neuron-glial cell differentiations.
    We found that the promoting osteogenic and chodrosphere formation function by GEG is mainly come from the Tortoise plastron (T.P.) ingredient and the vasculogenic effect by Radix Ginseng ( R.G.).
    In order to prevent use of T.P. component from the endangered specie animal, several substitute herb candidates have evaluated. Among the candidates we found Dipsacus asper (D.A.), Achyranthes bidentata (A.B.), and Drynaria fortunei (D.F.) are useful substitutes for T.P.
    Specifically, we found that D.F. as T.P. promotes the total hematopoietic colony forming activity, and Achyranthes bidentata (A.B.) shown promoting the Erythroid lineage differentiation and inhibits the Granulocyte and Macrophage lineage differentiation. In mesenchymal tissue responses, we found that D.F. and D.A. accelerate and increase the chondrosphere formation and S.M. and E.U. promote the vasculargenesis; We further confirmed that D.F. , A.B., and D.A have the ability to advance the bone mineralization. In the Functional genomic evaluation, we investigated that the IL-11 expression was down regulated and the BMP-2 and OPN gene expression enhanced by T.P., D.F. and A.B.. At the late stage of osteoblast differentiation, T.P. and D.F. shown enhance the gene expression of Type I collagen., but not the A.B.
    Althought the substitute T.P. component of GEG needed to be further studied by in vivo animal or clinical investigation, current study provides a cell based molecular pharmacological evidences for GEG prescription and three potential candidates for the T.P. substitute.
    数据类型: thesis
    显示于类别:[醫學科學研究所] 博碩士論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    摘要.doc31KbMicrosoft Word141检视/开启
    摘要.pdf129KbAdobe PDF217检视/开启
    摘要.ppt130KbMicrosoft Powerpoint258检视/开启
    摘要.ps925KbPostscript74检视/开启


    在TMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈